ArticleFood & nutrition research2022
Sporoderm-broken spore powder of
Article in Food & nutrition research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Comparative efficacy of Chinese patent medicines for non-alcoholic fatty liver disease: A network meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Plant oil complex: dual activation of peroxisome proliferator-activated receptors α andOpen life sciences · 2026Article
- A new lanostane-type triterpene with lipid-lowering activity from Ganoderma lucidum and an additional analogue.Frontiers in chemistry · 2025Article
- Article
- Developmental and reproductive toxicity assessment of sporoderm-removedFrontiers in cell and developmental biology · 2025Article
- Article
- The Anti-Inflammatory Effect ofInternational journal of molecular sciences · 2024Article
- Research progress of Ganoderma lucidum polysaccharide in prevention and treatment of Atherosclerosis.Heliyon · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study examined the anti-obesity and anti-inflammatory effects of sporoderm-broken spore powder of Methods: Four groups of C57BL/6J mice were randomly assigned to the following diets: control diet (CD); high-fat diet (HD); high-fat diet plus l-carnitine (HDL); and high-fat diet with sporoderm-broken spore powder of Results: Supplementation with SSPL lowered weight gain caused by a high-fat diet and improved serum and liver lipid levels, and histological investigation indicated that the HDG group had a significant reduction in liver lipid deposits and adipocyte size in epididymal fat. SSPL administration decreased the expression of genes associated with inflammation and fat anabolism, including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β), peroxisome proliferator-activated receptorγ (PPARγ), sterol regulatory element-binding protein 1c (SREBP-1c), fatty acid synthase (FAS), acetyl-coenzyme A (CoA) carboxylase (ACC), and leptin. SSPL therapy raised the levels of PPARα, carnitine palmitoyl-transferase 1 (CPT-1), acyl-CoA oxidase1 (ACOX1), and adiponectin. Conclusion: In summary, SSPL protected mice against developing obesity caused by increased fat intake by regulating inflammatory factors and lipid metabolism. Our findings indicate that SSPL is a potentially beneficial healthy meal for treating obesity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.